Liquidity remains under severe pressure as evidenced by a volatile OCF/NI ratio of -5.71 in 2026Q1, highlighting the firm's inability to generate consistent cash from core operations.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 |
|---|
| Cash from Operations | -295.81M | -189.23M | -320.03M | -405.97M | -500.54M | -503.83M | -427.34M | 3.6B | -142.47M | -147.03M | 239.4M | -114.59M | -75.56M | 522K | 64.1M | -11.99M | -18.57M | 6.3M | -8.21M | 371K | -9.31M | -3.89M | -2.71M |
| Operating CF Margin % | - | -17.01% | -116.1% | -169.35% | -207.48% | -103.91% | -89.39% | 430.82% | -49.32% | -115.69% | 184.84% | -289.64% | -108.92% | 0.38% | 47.04% | -12.51% | -15.17% | 6.77% | -10.66% | 0.56% | -26.48% | -34.58% | -34.85% |
| Operating CF Growth % | -135.49% | 40.87% | 21.17% | 18.89% | 0.65% | -17.9% | -111.88% | 2624.74% | 3.1% | -161.42% | 308.92% | -51.66% | -14574.14% | -99.19% | 634.6% | 35.44% | -394.67% | 176.78% | -2312.67% | 103.98% | -139.52% | -43.43% | - |
| Net Income | 488.78M | 320.9M | 74.08M | 211.7M | -217.99M | -103.23M | -305.44M | 166.42M | -29.26M | -115.7M | 54.01M | -118.41M | 33.21M | -11.02M | -6.61M | -32.94M | 1.03M | 1.66M | -15.21M | -21.87M | -11.81M | -6.65M | -3.61M |
| Depreciation & Amortization | -36.52M | 0 | 35.4M | 43.64M | 65.57M | 34.64M | 18.68M | 12.1M | 5.08M | 4.29M | 4.18M | 3.4M | 4.65M | 8.15M | 9.01M | 12.1M | 11.63M | 6.96M | 7.37M | 8.35M | 4.73M | 1.31M | 1M |
| Stock-Based Compensation | -12.66M | 0 | 0 | 56.72M | 88.51M | 70.73M | 79.96M | 0 | 26.76M | 16.54M | 11.03M | 5.04M | 2.95M | 2.74M | 2.09M | 2.04M | 2.42M | 2.64M | 1.33M | 1.08M | 703K | 0 | 0 |
| Deferred Taxes | 0 | 0 | -1.71M | 11.69M | 2.84M | 2.42M | 2.12M | 0 | 50K | 198K | 235K | -1.22M | 2.34M | -2.95M | 1.71M | -2.2M | -224K | 1.35M | 6.52M | -82K | -4.5M | 0 | 0 |
| Other Non-Cash Items | 184.56M | 375.54M | -362.76M | -37.28M | -60M | -78M | 131.22M | 265.57M | -11.71M | 26.22M | -65.27M | 30.69M | -68.69M | 154K | -2K | 297K | -4.74M | -1.39M | 367K | 3.37M | -2.56M | -546K | -64K |
| Working Capital Changes | -919.99M | -885.68M | -65.04M | -692.43M | -379.47M | -430.38M | -353.88M | 3.15B | -133.39M | -78.56M | 235.21M | -34.09M | -50.02M | 3.44M | 57.91M | 8.71M | -28.69M | -4.92M | -8.58M | 9.51M | 4.13M | 1.99M | -41K |
| Change in Receivables | -44.84M | 0 | -31.05M | -39.11M | 68.98M | 79.86M | -177.16M | -75.28M | -76K | -27.66M | -12.98M | -7.22M | -10.11M | 1.07M | -16.88M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | -17.55M | 0 | 23.04M | -24.08M | -34.59M | -21.17M | -100K | 22.38K | 3K | 22K | 25K | -44K | -32K | -39K | 291K | 942K | 344K | 1.26M | 502K | -1.45M | 293K | 943K | 51K |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 89.47M | 20M | 14.77M | 2.1M | -26.73M | 0 | 2.34M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | 258.91M | 219.35M | 220.6M | 71.19M | -1.25B | 541.24M | 757.29M | -4.22B | -15.91M | -549K | -7.29M | -4.3M | 120.61M | -8.96M | -6.44M | 2.92M | -20.18M | -4.74M | -9.86M | -5.96M | -2.47M | -3.92M | -148K |
| Capital Expenditures | -7.13M | 0 | -16.72M | -18.71M | -27.39M | -54.2M | -42.52M | -51.13M | -13.72M | -7.44M | -4.79M | -6.67M | -2.8M | -7.87M | -6.84M | -5.83M | -4.25M | -5.19M | -5.7M | -6.04M | -4.27M | -1.11M | -148K |
| CapEx % of Revenue | 0.68% | 1.18% | 6.07% | 7.8% | 11.35% | 11.18% | 8.89% | 6.12% | 4.75% | 5.85% | 3.7% | 16.85% | 4.04% | 5.72% | 5.02% | 6.08% | 3.47% | 5.57% | 7.41% | 9.17% | 12.14% | 9.88% | 1.9% |
| Acquisitions | -19.85M | 0 | 0 | -7M | -115.27M | 28.7M | 0 | 0 | 3.33M | 7K | 0 | 110K | 130.79M | -1.15M | 0 | 8.71M | -15.96M | 0 | -857K | 0 | 1.8M | -2.81M | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 150.71M | 219.35M | 237.32M | 16.62M | -15.82M | -3.66M | -45.24M | 0 | -3.32M | 6.52M | 253K | 2.37M | -7.38M | 65K | 399K | 44K | 35K | 443K | -3.3M | 80K | 0 | 0 | 0 |
| Cash from Financing | -2.77M | -3.14M | -4.92M | -5M | -1.49M | -3.88M | 22.04M | 1.5B | 287.88M | 353.36M | 396M | 271.37M | 4.21M | 55.82M | 4.03M | 633K | 31.16M | 18.52M | -3.92M | 3.4M | 39.77M | 21.16M | 96K |
| Debt Issued (Net) | -2.37M | 0 | -4.92M | -6.77M | -8.18M | -7.19M | -6.25M | -5.7M | -5K | -65K | -49K | -43K | -216K | -308K | -477K | -343K | -255K | -497K | -5.08M | -2.51M | -1.55M | -351K | -106K |
| Equity Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.5B | 296.19M | 363.92M | 392.12M | 278.7M | 0 | 54.8M | 2.74M | 553K | 0 | 0 | 0 | 0 | 40.95M | 21.14M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -405.35K | -3.14M | 0 | 1.77M | 6.7M | 3.31M | 28.29M | 0 | -8.31M | -10.5M | 3.92M | -7.29M | 4.43M | 0 | 0 | 423K | 31.41M | 18.65M | 1.16M | 5.91M | 0 | 368K | 202K |
| Net Change in Cash | -41.3M | -5.06M | -102.57M | -341.31M | -1.73B | 90.3M | 281.45M | 382.13M | 139.59M | 177.97M | 632.93M | 152.6M | 49.54M | 46.83M | 62.09M | -7.84M | -6.99M | 20.07M | -21.98M | -2.22M | 27.9M | 13.34M | -2.76M |
| Free Cash Flow | -304.55M | -202.4M | -402.14M | -425.24M | -537.49M | -561.71M | -518.65M | 3.57B | -156.18M | -154.47M | 234.61M | -121.25M | -78.36M | -7.35M | 57.27M | -17.82M | -22.83M | 1.12M | -13.91M | -5.67M | -13.58M | -5M | -2.86M |
| FCF Margin % | -29.18% | -18.2% | -145.89% | -177.39% | -222.8% | -115.85% | -108.49% | 427.82% | -54.07% | -121.54% | 181.14% | -306.49% | -112.96% | -5.34% | 42.03% | -18.59% | -18.65% | 1.2% | -18.07% | -8.61% | -38.62% | -44.47% | -36.75% |
| FCF Growth % | -19.66% | 49.67% | 5.43% | 20.88% | 4.31% | -8.3% | -114.52% | 2386.96% | -1.11% | -165.84% | 293.49% | -54.74% | -965.96% | -112.84% | 421.3% | 21.91% | -2143.51% | 108.03% | -145.17% | 58.21% | -171.63% | -74.88% | - |
| FCF per Share | -4.62 | -3.07 | -6.08 | -6.45 | -8.18 | -8.58 | -7.97 | 62.00 | -3.00 | -3.12 | 5.13 | -3.40 | -2.60 | -0.26 | 2.16 | -0.68 | -0.94 | 0.05 | -0.66 | -0.27 | -1.00 | -0.56 | -0.48 |
| FCF Conversion (FCF/Net Income) | -0.62x | -0.59x | -4.32x | -1.92x | 2.30x | 4.02x | 1.40x | 24.00x | 4.87x | 1.27x | 4.43x | 0.97x | -2.27x | -0.06x | -11.21x | 0.36x | -4.25x | 2.09x | 0.56x | -0.02x | 0.82x | 0.59x | 0.76x |
| Interest Paid | 0 | 0 | 689K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Liquidity and clinical failure
As reported in financial statements, the company consistently records negative operating cash flow despite intermittent net income spikes, with the OCF/NI ratio reaching a volatile -5.71 in 2026Q1, suggesting that reported profits are largely accounting artifacts rather than tangible cash generation from core operations.
The persistent gap between net income and operating cash flow indicates that the company's earnings are heavily influenced by non-cash items and milestone-based revenue recognition. Investors should monitor this divergence, as it implies that the underlying business model is not yet capable of self-funding its R&D-heavy cost structure.
Based on recent quarterly data, FCF margins have remained deeply negative, bottoming out at -173.0% in 2025Q2, which highlights the structural inability of the current commercial and collaboration-based revenue model to cover the substantial cash outflows required for ongoing clinical development and operational overhead.
The consistent negative FCF trajectory suggests that the company is in a state of perpetual cash consumption. This trend warrants further investigation into whether the pivot toward decentralized CAR-T manufacturing will eventually yield the operational efficiencies necessary to stabilize cash burn or if it will simply introduce new, unproven capital requirements.
According to the provided cash flow data, working capital changes have been highly erratic, including a massive $827.1M outflow in 2025Q4, which suggests significant instability in the timing of milestone payments and the management of liabilities associated with the Gilead collaboration agreement.
These wild swings in working capital appear to be the primary driver of the company's cash flow volatility rather than operational performance. The lack of predictability in these cash movements makes it difficult to forecast the company's runway and suggests that liquidity is highly sensitive to the timing of external partnership events.
As indicated by the historical cash flow statements, the company has engaged in sporadic acquisition activity, such as the $31.9M outflow in 2025Q1, despite a deteriorating cash position that may limit its ability to pursue further inorganic growth without dilutive financing or additional partnership capital.
The decision to deploy cash for acquisitions while operating cash flow remains negative suggests a high-risk strategy aimed at buying growth to offset internal pipeline setbacks. Investors should monitor whether these capital allocations provide a clear path to commercialization or if they represent an inefficient use of dwindling liquidity.
Quick answers to the most common questions about buying GLPG stock.
Galapagos N.V. (GLPG) generated $-189.2M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Galapagos N.V. (GLPG) reported negative free cash flow of $202.4M in 2025, indicating capital requirements exceeded cash from operations.
Galapagos N.V. (GLPG) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.